Novavax (NVAX) Q2 FY26 earnings call

Novavax reported a quarter marked by significant progress in its partnership strategy, particularly with Sanofi, and continued advancements in its Matrix-M technology platform. The company is successfully executing on its lean operating model, driving substantial cost reductions while strategically investing in R&D to broaden the utility of its adjuvant and generate new partnering opportunities. Management expressed confidence in its diversified revenue strategy and long-term value creation for shareholders.